Conference Details - Overview
Continuing Education Information
Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses: Physicians’ Education Resource is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Physicians’ Education Resource provides up to 12.34 contact hours for completion of this educational activity.
Pharmacists: Physicians’ Education Resource is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education.
Universal Program Numbers: 0464-9999-10-001-L01-P (Practical Hematopathology-T-Cell Lymphomas – 0.30 CEUs), 0464-9999-10-002-L01-P (Leukemia Session – 0.35 CEUs), 0464-9999-10-003-L01-P (Bone Marrow Transplantation Workshop – 0.225 CEUs), 0464-9999-10-004-L01-P (Lymphoma Session – 0.4 CEUs).
Credits: up to 12.75 contact hours (1.275 CEUs)
To receive credit, participants must attend the entire session and complete Activity Evaluation and Record of Attendance forms. Statements of credit will be validated on-site upon completion of the program.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.
Duke Debates: Controversies in the Management of Patients With Hematologic Malignancies
The Grove Park Inn Resort & Spa
Ashville, NC
April 9-11, 2010
Conference Overview
CME-, CNE-, and ACPE-Certified Symposium
This activity is presented by Physicians’ Education Resource in conjunction with Duke University Division of Cellular Therapy and Duke Oncology Network.
The Duke Debates: Controversies in the Management of Hematologic Malignancies symposium is designed to provide medical oncologists, hematologists, nurse practitioners, nurses, and other health care professionals with practical updates on recent advances and controversies in the management of hematologic malignancies.
This educational program is directed toward medical oncologists and hematologists interested in the treatment of patients with hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies are also invited to attend.At the conclusion of this symposium, you should be able to:
- Apply appropriate risk stratification measures to devise individualized treatment plans for patients with newly diagnosed leukemia, lymphoma, and myeloma
- Outline standard treatment options for patients with relapsed/refractory leukemia, lymphoma, and myeloma
- Evaluate the safety and efficacy of recent clinical advances in the management of patients with relapsed/refractory leukemia, lymphoma, and myeloma
- Debate the potential role of emerging novel agents for the treatment of patients with leukemia, lymphoma, and myeloma
- Recommend appropriate up-front or salvage hematopoietic stem cell transplantation for eligible patients with hematologic malignancies
Educational Grants
An educational grant for this activity was provided by:
- Cephalon Oncology
- Allos Therapeutics
- Celgene Corporation
- Eisai, Inc.
- Genzyme Oncology, a business unit of Genzyme Corporation
- Lilly USA, LLC
- Millennium Pharmaceuticals, Inc.
- Otsuka America Pharmaceutical, Inc.
- sanofi-aventis U.S.